VitsGen Therapeutics CSO Dr. Haihong Jin to Present Breakthrough for 2 RLT Programs at SNMMI 2025 Annual Meeting

1.    Vitsgen's First IND candidate ¹⁷⁷Lu-PSMA-VG-01 targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

^*177Lu-PSMA-VG-01 has 2.6-fold improvement in binding affinity, 2.4- fold better cell internalization, and higher tumor uptake and retention compared with ¹⁷⁷Lu-PSMA-617.

2.    Vitsgen's Second IND candidate ¹⁷⁷Lu-FAP-VG-01 targeting Fibroblast Activation Protein alpha (FAP) for the treatment of solid tumors.

^*177Lu-FAP-VG-01 has 2.6-fold improvement in binding affinity, ~7 fold higher tumor uptake and much improved retention time compared with clinical compound ¹⁷⁷Lu-FAP-2286.

VitsGen Philosophy

• To create best available therapies, to make a difference for patients:

• Best-in-class radiopharmaceutical attributes for success

•  Increased tumor uptake

• Longer tumor retention time

• Superior tumor/normal organs ratio

• To target the right tumor types, to help the most patients:

• First-in-class agents based on core expertise

• Experienced medicinal chemistry, proven optimization

• Applied deep understanding of cancer biology

VitsGen Advantages

• Peptide MAP Design Platform:

* Medicinal chemistry    * AI    * Phase Display

Our outstanding and experienced teams collaborate together and have created novel, best-in-class & first-in-class, peptide-based RDCs

• Multi-disciplinary expertise: dedicated teams across:

* Radiochemistry      * Radiobiology

* Peptide chemistry    * Metallodrug CMC

• Demonstrated execution: higher productivity with both speed and cost advantages:

*In <4 years, we have 7 active programs, 2 development candidates and 2 more projected in 2025

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

New Orleans Ernest N. Morial Convention Center, New Orleans LA, USA June 21-24, 2025.